Clinical

Findings from a 10-year research project show that implementing health initiatives at a population level can improve health and reduce the risk of heart disease for an entire community.

A comparison of neurocognitive profiles of patients with confirmed Niemann-Pick disease type C (NP-C) and early Alzheimer disease found that general dementia screening assessments should not be used alone to evaluate cognitive performance in patients with suspected NP-C since these patients may demonstrate milder cognitive deficits than patients with early Alzheimer disease.

The Joslin Diabetes Center published its new Clinical Guidelines in the June issue of Evidence-Based Diabetes Management™. Here, Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin, explains the development of the guidelines and the audience Joslin hopes to reach by publishing in journal.

An investigational drug has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia (AML).

Two recent studies evaluated the effects of asthma through addressing the costs and adherence to medications as well as the accessibility to certain resources for patients.

A new approach using gene editing technology could allow chimeric antigen receptor (CAR) T cells to target CD33 in patients with acute myeloid leukemia (AML) but prevent the cells from attacking healthy stem cells, too.

With few Americans receiving all the preventive services recommended for them, efforts across the full delivery system are needed to increase the use of preventive services, according to a paper published in Health Affairs.

An experimental drug for patients with acute myeloid leukemia (AML) with mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) was found to be safe with durable remissions.

Erenumab is the first calcitonin gene-related peptide (CGRP) inhibitor to be approved by the FDA for the prevention of migraine. The Institute for Clinical and Economic Review assessed the comparative effectiveness and value of erenumab with 2 other CGRP inhibitors that are still under FDA review.

Two studies presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting investigated the economic and clinical burdens on patients diagnosed with migraine.